LUMINOSITY
The single-arm study behind the first c-Met-directed antibody-drug conjugate approval in lung cancer: tumours shrank in about a third of patients whose cancers carried high c-Met protein, with eye and nerve side effects to watch.
Overview
LUMINOSITY, trial NCT03539536 sponsored by AbbVie and published in the Journal of Clinical Oncology in 2024, gave telisotuzumab vedotin to previously treated patients with non-squamous, EGFR wild-type non-small-cell lung cancer whose tumours overexpressed c-Met protein on immunohistochemistry. The objective response rate was 28.6% overall, 34.6% in the c-Met high group and 22.9% in the intermediate group, with peripheral sensory neuropathy, peripheral oedema and keratitis among the notable side effects. The c-Met high results supported the 2025 US accelerated approval of Emrelis, the first c-Met-directed ADC in lung cancer; the confirmatory phase 3 trial TeliMET NSCLC-01 is ongoing.
- 34.6 vs 22.9 out of 100 had their tumour shrink with Telisotuzumab vedotin, c-Met high compared with Telisotuzumab vedotin, c-Met intermediate; 11.7 more per 100.
- Roughly one extra person helped for every 9 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: Previously treated c-Met protein-overexpressing, EGFR wild-type non-squamous NSCLC: telisotuzumab vedotin single arm. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (Met); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
270 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective response rate (independent review)primary | Telisotuzumab vedotin, c-Met high | 78 | 34.6% | - | - | link |
| Telisotuzumab vedotin, c-Met intermediate | 83 | 22.9% |
Similar pages
not linked directly; found by shared links- TrialTeliMET NSCLC-01
Shares Telisotuzumab vedotin, MET, Non-small-cell lung cancer.
- TreatmentJS111
Shares MET, Non-small-cell lung cancer.
- TermMET amplification (bypass resistance)
Shares Telisotuzumab vedotin, MET, Non-small-cell lung cancer.
- TreatmentTQB6411
Shares MET, Non-small-cell lung cancer.
- CompanyMythic Therapeutics
Shares MET, Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
- TreatmentHS-20117
Shares MET, Non-small-cell lung cancer.
- PersonJürgen Wolf
Shares MET, Non-small-cell lung cancer.
- TreatmentCapmatinib & tepotinib
Shares MET, Non-small-cell lung cancer.